A PYMNTS Company

Antitrust EpiPen MDL Case Given Partly Class Status

By  |  February 27, 2020

Part of the multidistrict lawsuit over EpiPen price gouging, which involves racketeering and antitrust claims against Mylan NV, was certified as a class action Thursday by a Kansas federal judge, who also declined to let other EpiPen buyers proceed collectively, reported Bloomberg.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    EpiPen, an epinephrine auto-injector that treats potentially fatal allergic reactions, has been a poster child for drug price-gouging since an uproar in 2016 over its increase from $50 a shot to $300.

    The sprawling consolidated suit includes parallel proposed class actions on behalf of patients, insurers, and plan sponsors like employers, as well as individual claims by competitors.

    Full Content: Financial Times

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.